Waseem Qasim

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1606562/waseem-qasim-publications-by-year.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116 papers	4,974 citations	38 h-index	67 g-index
126 ext. papers	6,083 ext. citations	6.4 avg, IF	5.22 L-index

#	Paper	IF	Citations
116	Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells **2022**, 51-54		
115	Off-the-Shelf CAR-T. *Cancer Drug Discovery and Development*, **2022**, 109-120	0.3	0
114	TT52CAR19: Phase 1 Trial of CRISPR/Cas9 Edited Allogeneic CAR19 T Cells for Paediatric Relapsed/Refractory B-ALL. *Blood*, **2021**, 138, 4838-4838	2.2	1
113	FOXN1 forms higher-order nuclear condensates displaced by mutations causing immunodeficiency. *Science Advances*, **2021**, 7, eabj9247	14.3	1
112	Ex vivo gene modification therapy for genetic skin diseases-recent advances in gene modification technologies and delivery. *Experimental Dermatology*, **2021**, 30, 887-896	4	5
111	Base-edited CAR T cells for combinational therapy against T cell malignancies. *Leukemia*, **2021**, 35, 3466-3481	11.4	13
110	The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults. *British Journal of Haematology*, **2021**, 192, e42-e44	4.5	
109	Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency. *Journal of Clinical Immunology*, **2021**, 41, 171-184	5.7	3
108	CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity. *Molecular Therapy - Methods and Clinical Development*, **2020**, 19, 149-161	6.4	5
107	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. *Lancet, The*, **2020**, 396, 1885-1894	40	71
106	New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. *Blood Advances*, **2020**, 4, 2418-2429	7.8	5
105	3MiniSU6 Pol III promoter exhibits nucleosome redundancy and supports multiplexed coupling of CRISPR/Cas9 effects. *Gene Therapy*, **2020**, 27, 451-458	4	2
104	Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 901-911	11.5	29
103	Lentiviral Vector Production Titer Is Not Limited in HEK293T by Induced Intracellular Innate Immunity. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 209-219	6.4	10
102	CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells. *Communications Biology*, **2020**, 3, 375	6.7	13
101	Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety. *Molecular Therapy*, **2020**, 28, 1422-1431	11.7	18
100	Human Mesenchymal Stromal Cells Engineered to Express Collagen VII Can Restore Anchoring Fibrils in Recessive Dystrophic Epidermolysis Bullosa Skin Graft Chimeras. *Journal of Investigative Dermatology*, **2020**, 140, 121-131.e6	4.3	9

99	Emerging therapeutic applications of CRISPR genome editing. *Emerging Topics in Life Sciences*, **2019**, 3, 257-260	3.5	1
98	Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources. *Expert Review of Clinical Immunology*, **2019**, 15, 735-751	5.1	16
97	Impaired EIF2S3 function associated with a novel phenotype of X-linked hypopituitarism with glucose dysregulation. *EBioMedicine*, **2019**, 42, 470-480	8.8	24
96	New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 280-293	11.5	25
95	Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia. *American Journal of Human Genetics*, **2019**, 104, 948-956	11	17
94	Hematopoietic stem cell transplantation for cytidine triphosphate synthase 1 (CTPS1) deficiency. *Bone Marrow Transplantation*, **2019**, 54, 130-133	4.4	10
93	Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial. *Human Gene Therapy*, **2019**, 30, 1067-1078	4.8	15
92	Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. *JCI Insight*, **2019**, 4,	9.9	30
91	Allogeneic CAR T cell therapies for leukemia. *American Journal of Hematology*, **2019**, 94, S50-S54	7.1	35
90	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1036-1049.e5	11.5	157
89	Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 2319-2321.e1	11.5	4
88	Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects. *Molecular Therapy*, **2018**, 26, 1215-1227	11.7	68
87	Loss-of-function nuclear factor B subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 1285-1296	11.5	109
86	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. *American Journal of Human Genetics*, **2018**, 103, 3-18	11	27
85	TCR/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. *JCI Insight*, **2018**, 3,	9.9	41
84	Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 896-896	2.2	52
83	Administration of BPX-501 Cells Following AT and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias. *Blood*, **2018**, 132, 307-307	2.2	4
82	Administration of BPX-501 Cells Following T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders. *Blood*, **2018**, 132, 2171-2171	2.2	

81	Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 529-536	4.7	51
80	T-cell receptor α/β and CD19 cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1417-1426.e1	11.5	85
79	One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 1654-1656.e7	11.5	29
78	Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation. *Cytotherapy*, **2018**, 20, 830-838	4.8	9
77	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. *American Journal of Human Genetics*, **2018**, 103, 144-153	11	18
76	Umbilical cord blood transplantation without in vivo T-cell depletion for children with MHC class II deficiency. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 2279-2282.e2	11.5	11
75	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. *American Journal of Human Genetics*, **2017**, 100, 334-342	11	14
74	Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Science Translational Medicine*, **2017**, 9,	17.5	524
73	Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations. *Blood*, **2017**, 129, 1458-1468	2.2	64
72	Genome-Edited T Cell Therapies. *Current Stem Cell Reports*, **2017**, 3, 124-136	1.8	9
71	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. *American Journal of Human Genetics*, **2017**, 100, 75-90	11	235
70	Gene Modified T Cell Therapies for Hematological Malignancies. *Hematology/Oncology Clinics of North America*, **2017**, 31, 913-926	3.1	2
69	Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic /NEMO mutations. *Blood*, **2017**, 130, 1456-1467	2.2	61
68	Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis. *Acta Neuropathologica*, **2017**, 133, 139-147	14.3	29
67	Mutations in linker for activation of T cells (LAT) lead to a novel form of severe combined immunodeficiency. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 634-642.e5	11.5	24
66	Cord blood transplantation recapitulates fetal ontogeny with a distinct molecular signature that supports CD4 T-cell reconstitution. *Blood Advances*, **2017**, 1, 2206-2216	7.8	17
65	Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. *Journal of Clinical Investigation*, **2017**, 127, 1991-2006	15.9	73
64	Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1152-1160	11.5	22

63	Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB. *Journal of Investigative Dermatology*, **2016**, 136, 284-92	4.3	34
62	Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) after T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (haplo-HSCT). *Blood*, **2016**, 128, 72-72	2.2	1
61	Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. *Cytotherapy*, **2016**, 18, 1002-1011	4.8	114
60	Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications. *Cytotherapy*, **2016**, 18, 1209-18	4.8	11
59	Human Coronavirus OC43 Associated with Fatal Encephalitis. *New England Journal of Medicine*, **2016**, 375, 497-8	59.2	176
58	Reply to: "To target or not to target viral antigens in HBV related HCC?". *Journal of Hepatology*, **2015**, 62, 1450-2	13.4	3
57	Variable phenotype of severe immunodeficiencies associated with RMRP gene mutations. *Journal of Clinical Immunology*, **2015**, 35, 147-57	5.7	15
56	Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission. *Brain*, **2015**, 138, 2834-46	11.2	59
55	Engineered T cell therapies. *Expert Reviews in Molecular Medicine*, **2015**, 17, e19	6.7	5
54	Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. *Blood*, **2015**, 126, 2882-91	2.2	52
53	T cell receptor-therapy in HBV-related hepatocellularcarcinoma. *OncoImmunology*, **2015**, 4, e1008354	7.2	27
52	Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. *Human Gene Therapy*, **2015**, 26, 276-85	4.8	11
51	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. *Journal of Hepatology*, **2015**, 62, 486-91	13.4	123
50	Astrovirus VA1/HMO-C: an increasingly recognized neurotropic pathogen in immunocompromised patients. *Clinical Infectious Diseases*, **2015**, 60, 881-8	11.6	139
49	Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial. *Blood*, **2015**, 126, 1931-1931	2.2	2
48	First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL. *Blood*, **2015**, 126, 2046-2046	2.2	61
47	Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. *Scientific Reports*, **2014**, 4, 6409	4.9	42
46	Gene therapy for primary immunodeficiencies: current status and future prospects. *Drugs*, **2014**, 74, 963-9	12.1	24

45	Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients. *Clinical Infectious Diseases*, **2014**, 58, 1700-6	11.6	25
44	"Darwinian" tumor-suppression model unsupported in clinical experience. *Molecular Therapy*, **2014**, 22, 1562-3	11.7	5
43	Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. *Viruses*, **2014**, 6, 243-63	3.2	25
42	Progress and prospects for engineered T cell therapies. *British Journal of Haematology*, **2014**, 166, 818-29	4.5	13
41	Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 1660-6	11.5	38
40	Gene therapies for inherited skin disorders. *Seminars in Cutaneous Medicine and Surgery*, **2014**, 33, 83-90	1.4	15
39	Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. *Bone Marrow Transplantation*, **2013**, 48, 803-8	4.4	99
38	How I treat severe combined immunodeficiency. *Blood*, **2013**, 122, 3749-58	2.2	67
37	22q11.2 deletion syndrome with life-threatening adenovirus infection. *Journal of Pediatrics*, **2013**, 163, 908-10	3.6	9
36	Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. *Human Gene Therapy Clinical Development*, **2013**, 24, 182-90	3.2	30
35	Alternative donor SCT for the treatment of MHC class II deficiency. *Bone Marrow Transplantation*, **2013**, 48, 226-32	4.4	17
34	Interferon-□apture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation. *British Journal of Haematology*, **2013**, 161, 449-52	4.5	28
33	Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation. *Advances in Hematology*, **2013**, 2013, 176418	1.5	24
32	Comparison of lentiviral and sleeping beauty mediated □T cell receptor gene transfer. *PLoS ONE*, **2013**, 8, e68201	3.7	33
31	Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene. *PLoS ONE*, **2013**, 8, e77106	3.7	21
30	Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. *British Journal of Haematology*, **2012**, 156, 656-66	4.5	94
29	Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor. *Human Gene Therapy*, **2012**, 23, 1176-85	4.8	17
28	Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression. *Human Gene Therapy*, **2012**, 23, 83-90	4.8	9

27	Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. *Blood*, **2011**, 117, 4367-75	2.2	124
26	Autologous transplantation of amniotic fluid-derived mesenchymal stem cells into sheep fetuses. *Cell Transplantation*, **2011**, 20, 1015-31	4	61
25	Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. *Blood*, **2011**, 118, 1675-84	2.2	236
24	Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. *British Journal of Haematology*, **2011**, 154, 150-3	4.5	45
23	Clinical and immunological manifestations of patients with atypical severe combined immunodeficiency. *Clinical Immunology*, **2011**, 141, 73-82	9	122
22	Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. *Molecular Therapy*, **2011**, 19, 408-16	11.7	52
21	FOXRED1, encoding an FAD-dependent oxidoreductase complex-I-specific molecular chaperone, is mutated in infantile-onset mitochondrial encephalopathy. *Human Molecular Genetics*, **2010**, 19, 4837-47	5.6	73
20	Hybrid lentiviral vectors. *Molecular Therapy*, **2010**, 18, 1263-7	11.7	11
19	Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation. *Blood*, **2010**, 116, 27-35	2.2	45
18	Rapid Expansion of Naive CD4+ Cord Blood Lymphocytes Restores Adaptive Immunity within 2 Months After Unrelated Cord Blood Transplantation. *Blood*, **2010**, 116, 2337-2337	2.2	
17	Sleeping beauty transposition from nonintegrating lentivirus. *Molecular Therapy*, **2009**, 17, 1197-204	11.7	59
16	Progress and prospects: gene therapy for inherited immunodeficiencies. *Gene Therapy*, **2009**, 16, 1285-91	4	59
15	Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. *Pediatrics*, **2009**, 123, 836-40	7.4	99
14	Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. *Human Gene Therapy*, **2008**, 19, 699-709	4.8	8
13	Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome. *Pediatrics*, **2008**, 121, e998-1002	7.4	46
12	Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector. *Gene Therapy*, **2007**, 14, 1623-31	4	19
11	Capture and generation of adenovirus specific T cells for adoptive immunotherapy. *British Journal of Haematology*, **2007**, 136, 117-26	4.5	34
10	Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. *Molecular Therapy*, **2007**, 15, 355-60	11.7	34

9	Update on clinical gene therapy in childhood. *Archives of Disease in Childhood*, **2007**, 92, 1028-31	2.2	10
8	Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. *Blood*, **2005**, 106, 3062-7	2.2	161
7	T cell suicide gene therapy to aid haematopoietic stem cell transplantation. *Current Gene Therapy*, **2005**, 5, 121-32	4.3	9
6	Gene therapy for severe combined immune deficiency. *Expert Reviews in Molecular Medicine*, **2004**, 6, 1-15	6.7	19
5	The impact of retroviral suicide gene transduction procedures on T cells. *British Journal of Haematology*, **2003**, 123, 712-9	4.5	6
4	T cell transduction and suicide with an enhanced mutant thymidine kinase. *Gene Therapy*, **2002**, 9, 824-7	4	26
3	Protein assays for diagnosis of Wiskott-Aldrich syndrome and X-linked thrombocytopenia. *British Journal of Haematology*, **2001**, 113, 861-5	4.5	12
2	Anticardiolipin antibodies and thromboembolism after BMT. *Bone Marrow Transplantation*, **1998**, 21, 845-7	4.4	15
1	Base-edited CAR T Cells for combinational therapy against T cell malignancies		1